Functional interaction of tumor suppressor DLC1 and caveolin-1 in cancer cells.

Deleted in liver cancer 1 (DLC1), a tumor suppressor gene frequently inactivated in non-small cell lung cancer (NSCLC) and other malignancies, encodes a multidomain protein with a RhoGTPase-activating (RhoGAP) domain and a StAR-related lipid transfer (START) domain. However, no interacting macromolecule has been mapped to the DLC1 START domain. Caveolin-1 (CAV-1) functions as a tumor suppressor in most contexts and forms a complex with DLC1. Here, we have mapped the region of DLC1 required for interaction with CAV-1 to the DLC1 START domain. Mutation of the DLC1 START domain disrupted the interaction and colocalization with CAV-1. Moreover, DLC1 with a START domain mutation failed to suppress neoplastic growth, although it negatively regulated active Rho. CAV-1 and DLC1 expression levels were correlated in two public datasets of NSCLC lines and in two independent publicly available mRNA expression datasets of NSCLC tumors. Clinically, low DLC1 expression predicted a poor clinical outcome in patients with lung cancer. Together, our findings indicate that complex formation between the DLC1 START domain and CAV-1 contributes to DLC1 tumor suppression via a RhoGAP-independent mechanism, and suggest that DLC1 inactivation probably contributes to cancer progression.

[1]  B. J. Clark,et al.  The mammalian START domain protein family in lipid transport in health and disease. , 2012, The Journal of endocrinology.

[2]  I. Ng,et al.  Caveolin‐1 overexpression is associated with hepatocellular carcinoma tumourigenesis and metastasis , 2012, The Journal of pathology.

[3]  D. Lowy,et al.  Full activity of the deleted in liver cancer 1 (DLC1) tumor suppressor depends on an LD-like motif that binds talin and focal adhesion kinase (FAK) , 2011, Proceedings of the National Academy of Sciences.

[4]  Keith Burridge,et al.  The 'invisible hand': regulation of RHO GTPases by RHOGDIs , 2011, Nature Reviews Molecular Cell Biology.

[5]  D. Zimonjic,et al.  DLC1 interaction with S100A10 mediates inhibition of in vitro cell invasion and tumorigenicity of lung cancer cells through a RhoGAP-independent mechanism. , 2011, Cancer research.

[6]  J. Cherfils,et al.  Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy? , 2010, Nature Reviews Cancer.

[7]  L. Giménez,et al.  Multiplexed methylation profiles of tumor suppressor genes and clinical outcome in lung cancer , 2010, Journal of Translational Medicine.

[8]  L. Diao,et al.  Caveolin-1 and VEGF-C promote Lymph Node Metastasis in the Absence of Intratumoral Lymphangiogenesis in Non-small Cell Lung Cancer , 2010, Tumori.

[9]  M. Shatz,et al.  Caveolin-1 mutants P132L and Y14F are dominant negative regulators of invasion, migration and aggregation in H1299 lung cancer cells. , 2010, Experimental cell research.

[10]  H. Sugimoto,et al.  StarD7 Mediates the Intracellular Trafficking of Phosphatidylcholine to Mitochondria* , 2009, The Journal of Biological Chemistry.

[11]  R. Karlsson,et al.  Rho GTPase function in tumorigenesis. , 2009, Biochimica et biophysica acta.

[12]  D. Lowy,et al.  The Tensin-3 protein, including its SH2 domain, is phosphorylated by Src and contributes to tumorigenesis and metastasis. , 2009, Cancer cell.

[13]  I. Ng,et al.  Deleted in Liver Cancer 1 (DLC1) Utilizes a Novel Binding Site for Tensin2 PTB Domain Interaction and Is Required for Tumor-Suppressive Function , 2009, PloS one.

[14]  D. Lowy,et al.  p120Ras-GAP binds the DLC1 Rho-GAP tumor suppressor protein and inhibits its RhoA GTPase and growth-suppressing activities , 2009, Oncogene.

[15]  C. Der,et al.  Role of DLC-1, a tumor suppressor protein with RhoGAP activity, in regulation of the cytoskeleton and cell motility , 2009, Cancer and Metastasis Reviews.

[16]  Boon Chuan Low,et al.  The SAM domain of the RhoGAP DLC1 binds EF1A1 to regulate cell migration , 2009, Journal of Cell Science.

[17]  Monilola A. Olayioye,et al.  Deleted in liver cancer 1 controls cell migration through a Dia1-dependent signaling pathway. , 2008, Cancer research.

[18]  T. Godfrey,et al.  Whole genome exon arrays identify differential expression of alternatively spliced, cancer-related genes in lung cancer , 2008, Nucleic acids research.

[19]  A. Tonevitsky,et al.  Differences in gene expression levels between early and later stages of human lung development are opposite to those between normal lung tissue and non-small lung cell carcinoma. , 2008, Lung cancer.

[20]  S. Lo,et al.  Mutations in the focal adhesion targeting region of deleted in liver cancer-1 attenuate their expression and function. , 2008, Cancer research.

[21]  Igor Jurisica,et al.  Gene expression–based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study , 2008, Nature Medicine.

[22]  S. Wiseman,et al.  Caveolin-1 in tumor progression: the good, the bad and the ugly , 2008, Cancer and Metastasis Reviews.

[23]  John G. Collard,et al.  Rho GTPases: functions and association with cancer , 2007, Clinical & Experimental Metastasis.

[24]  C. Ukomadu,et al.  Interacting Proteins Dictate Function of the Minimal START Domain Phosphatidylcholine Transfer Protein/StarD2* , 2007, Journal of Biological Chemistry.

[25]  Douglas R Lowy,et al.  DLC-1:a Rho GTPase-activating protein and tumour suppressor , 2007, Journal of cellular and molecular medicine.

[26]  M. Guan,et al.  Deleted in liver cancer 3 (DLC-3), a novel Rho GTPase-activating protein, is downregulated in cancer and inhibits tumor cell growth , 2007, Oncogene.

[27]  Kenneth M. Yamada,et al.  Oncogenic inhibition by a deleted in liver cancer gene requires cooperation between tensin binding and Rho-specific GTPase-activating protein activities , 2007, Proceedings of the National Academy of Sciences.

[28]  S. Lo,et al.  The phosphotyrosine-independent interaction of DLC-1 and the SH2 domain of cten regulates focal adhesion localization and growth suppression activity of DLC-1 , 2007, The Journal of cell biology.

[29]  I. Ng,et al.  Interaction of deleted in liver cancer 1 with tensin2 in caveolae and implications in tumor suppression. , 2006, Cancer research.

[30]  I. Ng,et al.  Rho GTPase-activating protein deleted in liver cancer suppresses cell proliferation and invasion in hepatocellular carcinoma. , 2005, Cancer research.

[31]  Monilola A. Olayioye,et al.  StarD10, a START Domain Protein Overexpressed in Breast Cancer, Functions as a Phospholipid Transfer Protein*[boxs] , 2005, Journal of Biological Chemistry.

[32]  C. Tomasetto,et al.  Give lipids a START: the StAR-related lipid transfer (START) domain in mammals , 2005, Journal of Cell Science.

[33]  S. Okushiba,et al.  Difference of caveolin-1 expression pattern in human lung neoplastic tissue. Atypical adenomatous hyperplasia, adenocarcinoma and squamous cell carcinoma. , 2004, Cancer letters.

[34]  D. Lowy,et al.  Efficient Intracellular Assembly of Papillomaviral Vectors , 2004, Journal of Virology.

[35]  M. Fujii,et al.  A PLCδ1‐binding protein, p122/RhoGAP, is localized in caveolin‐enriched membrane domains and regulates caveolin internalization , 2004, Genes to cells : devoted to molecular & cellular mechanisms.

[36]  Satoshi Yasuda,et al.  Molecular machinery for non-vesicular trafficking of ceramide , 2003, Nature.

[37]  Yoon-La Choi,et al.  Expression of caveolin-1 is associated with poor prognosis of patients with squamous cell carcinoma of the lung. , 2003, Lung cancer.

[38]  M. Lisanti,et al.  Expression of caveolin-1 and caveolin-2 in urothelial carcinoma of the urinary bladder correlates with tumor grade and squamous differentiation. , 2003, American journal of clinical pathology.

[39]  T. Timme,et al.  Caveolin‐1 expression is a predictor of recurrence‐free survival in pT2N0 prostate carcinoma diagnosed in Japanese patients , 2003, Cancer.

[40]  S. Okushiba,et al.  Overexpression of caveolin‐1 in esophageal squamous cell carcinoma correlates with lymph node metastasis and pathologic stage , 2002, Cancer.

[41]  M. Lisanti,et al.  Caveolin-deficient mice: insights into caveolar function human disease. , 2001, The Journal of clinical investigation.

[42]  M. Robinson,et al.  Caveolin-1 expression is associated with high-grade bladder cancer. , 2001, Urology.

[43]  S. Law,et al.  Profiling of differentially expressed cancer-related genes in esophageal squamous cell carcinoma (ESCC) using human cancer cDNA arrays: overexpression of oncogene MET correlates with tumor differentiation in ESCC. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[44]  D. Lowy,et al.  Ras-Specific Exchange Factor GRF: Oligomerization through Its Dbl Homology Domain and Calcium-Dependent Activation of Raf , 1999, Molecular and Cellular Biology.

[45]  M. Kattan,et al.  Elevated expression of caveolin is associated with prostate and breast cancer. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[46]  S. Thorgeirsson,et al.  Cloning, characterization, and chromosomal localization of a gene frequently deleted in human liver cancer (DLC-1) homologous to rat RhoGAP. , 1998, Cancer research.

[47]  J. Glenney Tyrosine phosphorylation of a 22-kDa protein is correlated with transformation by Rous sarcoma virus. , 1989, The Journal of biological chemistry.

[48]  M. Sharma,et al.  Loss of DLC1 is an independent prognostic factor in patients with oral squamous cell carcinoma , 2012, Modern Pathology.

[49]  P. Lavigne,et al.  Mammalian StAR-related lipid transfer (START) domains with specificity for cholesterol: structural conservation and mechanism of reversible binding. , 2010, Sub-cellular biochemistry.

[50]  S. Lo,et al.  Deleted in liver cancer-1 (DLC-1): a tumor suppressor not just for liver. , 2008, The international journal of biochemistry & cell biology.